Accumulating evidence has demonstrated that decreased or lost KAI1 expression should associate with metastasis and prognosis in various tumors, including laryngeal carcinoma [20], prostate carcinoma [19, 21], breast carcinoma [22], lung carcinoma [23], gastric carcinoma [24], colon carcinoma [25], and hepatocellular carcinoma [26]. This evidence concerns the gene CD82 and prostate carcinoma.